Page last updated: 2024-11-04

xanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1188
CHEMBL ID1424
CHEBI ID17712
CHEBI ID48517
SCHEMBL ID4965
MeSH IDM0029424

Synonyms (121)

Synonym
MOLMAP_000070
XAN ,
3,9-dihydro-1h-purine-2,6-dione
9h-xanthine
2,6-dihydroxypurine
CHEBI:17712 ,
purine-2(3h),6(1h)-dione
9h-purine-2,6-(1h,3h)-dione
2,6-dioxo-1,2,3,6-tetrahydropurine
1h-purine-2,6-dione, 3,7-dihydro-
1h-purine-2,6-diol
3,7-dihydropurine-2,6-dione
SDCCGMLS-0065805.P001
nsc-14664
pseudoxanthine
9h-purine-2,3h)-dione
xanthic oxide
purine-2,3h)-dione
isoxanthine
xanthin
nsc14664
2,2,3,6-tetrahydropurine
2,6-dioxo-1,2,3, 6-tetrahydropurine
2,6-dioxypurine
3,7-dihydro-1h-purine-2,6-dione
C00385
2,6-dioxopurine
69-89-6
xanthine ,
2-oxohypoxanthine
3,9-dihydropurine-2,6-dione
3,9-dihydro-purine-2,6-dione
xanthine, bioultra, >=99%
xanthine, >=99%
xanthine, >=99.5% (hplc), purified by recrystallization
DB02134
NCGC00164338-01
nsc 14664
ai3-52268
xanthine (van)
purine-2,6-diol
9h-purine-2,6-diol
usaf cb-17
epa pesticide chemical code 116900
2,6(1,3)-purinedion
purine-2,6-(1h,3h)-dione
einecs 200-718-6
ccris 994
OPREA1_474175
CHEBI:48517
7h-xanthine
X-0950
92AB342E-6550-4B2B-AD76-E75AC1C2EB45
lrfvtywoqmyalw-uhfffaoysa-
inchi=1/c5h4n4o2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1h,(h3,6,7,8,9,10,11)
AKOS000498219
STL064827
CHEMBL1424 ,
xanthine (van) (8ci)
BMSE000127
X0004
AB00171825-02
HMS1659G11
A836687
bdbm82009
cas_1188
nsc_1188
AKOS005208756
3,7-dihydro-purine-2,6-dione
1h-purine-2,6(3h,7h)-dione
1avz07u9s7 ,
1h-purine-2,6-dione, 3,9-dihydro-
unii-1avz07u9s7
FT-0631300
2,3,6,9-tetrahydro-1h-purine-2,6-dione
FS-3231
9h-purine-2,6(1h,3h)-dione
xanthine [mi]
xanthine [inci]
xanthine [who-dd]
1h,3h,7h-xanthine
1h,3h,9h-xanthine
purine-2,6(1h,3h)-dione
2UZ9
AKOS015896921
gtpl4557
1h-purine-2,6(3h, 7h)-dione
AM83905
BBL028159
SCHEMBL4965
dioxypurin
cambridge id 5126190
CS-W018105
HMS3604G12
DTXSID4035120
mfcd00078453
STL453051
2,3,6,7-tetrahydro-1h-purine-2,6-dione
AC-8422
xanthine, 98%
xanthine, p.a., 99%
2,6-dihydroxypurin
Z57825360
dioxopurine
HY-W017389
SY030113
xanthine-13c15n2
1262670-81-4
S3693
7h-purine-2,6-diol
1h-purine-2,6(3h,9h)-dione
xanthine,(s)
BCP15189
bdbm50227193
Q50980
AMY239
EN300-18289
CCG-266216
cid 5280342
D71218
2,6-dihydroxypurine; isoxanthine

Research Excerpts

Overview

Xanthine is a plant alkaloid which also acts as an intermediate product on the pathway of purine degradation. Xanthine, which is a better substrate for xanthine oxidase than is NADH, causes a V(V)-dependent co-oxidation of NADH.

ExcerptReferenceRelevance
"Xanthine is a ligand for the transcription factor MftR that leads to attenuated DNA binding, and we show using chromatin immunoprecipitation that MftR binds directly to malR."( Impaired purine homeostasis plays a primary role in trimethoprim-mediated induction of virulence genes in Burkholderia thailandensis.
Grove, A; Thapa, SS, 2021
)
1.34
"Xanthine is a plant alkaloid which also acts as an intermediate product on the pathway of purine degradation."( Identification of Xanthine Derivatives as Inhibitors of Phosphodiesterase 9A Through In silico and Biological Studies.
Patra, S; Singh, N, 2018
)
1.54
"Xanthine is an additional substrate for the Plasmodium falciparum HGXPRT."( Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes.
Balaram, H; Shivashankar, K; Sujay Subbayya, IN; Sukumaran, S, 2000
)
1.28
"Xanthine, which is a better substrate for xanthine oxidase than is NADH, causes a V(V)-dependent co-oxidation of NADH which is transient and eliminated by SOD."( Effects of vanadate on the oxidation of NADH by xanthine oxidase.
Fridovich, I; Ivancheva, E; Liochev, S, 1989
)
1.25

Effects

Xanthine oxidase (XO) has been hypothesized to be a potential source of oxygen-derived free radicals during reperfusion of ischemic myocardium. Hypoxanthine has been proposed as a better indicator of hypoxic damage than acid-base status or lactate.

ExcerptReferenceRelevance
"Xanthine derivatives have been used to treat a variety of medical conditions including respiratory disease and neural degeneration. "( Stimulatory Effects of KPR-A148 on Osteoblast Differentiation and Bone Regeneration.
Kim, JA; Lee, D; Lee, T; Lim, J; Lim, S; Nam, SH; Park, EK, 2019
)
1.96
"Xanthine oxidase has long been considered to be subject to inhibition by excess substrate. "( Excess substrate inhibition of xanthine oxidase: a reexamination.
Fridovich, I; Hausladen, A, 1993
)
2.01
"Xanthine oxidase (XO) has been hypothesized to be a potential source of oxygen-derived free radicals during reperfusion of ischemic myocardium based on the fact that allopurinol, a XO-inhibitor, can reduce reperfusion injury. "( Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage.
Clement, R; Das, DK; Engelman, RM; Otani, H; Prasad, MR; Rao, PS, 1987
)
2.15
"Hypoxanthine has been proposed as a better indicator of hypoxic damage than acid-base status or lactate. "( Changes in acid-base status, lactate concentration and purine metabolites during reconstructive aortic surgery.
Fredholm, BB; Hohlbach, G; Schoenberg, MH, 1985
)
0.83

Actions

Xanthine had a much lower inhibitory effect on the conversion of guanine and hypoxanthine to the nucleotides. Adenine had no effect at all.

ExcerptReferenceRelevance
"Xanthine produced an increase in the contractility of isolated perfused rabbit's heart."( Cardiac depressant effects of oxygen free radicals.
Bharadwaj, L; Kalra, J; Prasad, K, 1993
)
1.01
"Xanthine had a much lower inhibitory effect on the conversion of guanine and hypoxanthine to the nucleotides, whereas adenine had no effect at all."( Hypoxanthine, guanine, xanthine phosphoribosyltransferase activity in Cryptosporidium parvum.
Doyle, PS; Kanaani, J; Wang, CC, 1998
)
1.58

Treatment

ExcerptReferenceRelevance
"Treatment with xanthine/xanthine oxidase for 15 min induced a 2.8 +/- 0.4-fold increase (n = 12, p less than 0.05) of t-PA antigen secretion after 24 h."( Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals.
Collen, D; Doherty, JM; Hoak, JC; Orfeo, T; Shatos, MA; Stump, DC, 1992
)
0.62

Toxicity

ExcerptReferenceRelevance
" We conclude that in vitro oxygen metabolites, extracellularly generated, have a direct toxic effect on gastric mucosal cells; hydrogen peroxide is a major mediator of oxygen metabolite-induced gastric cell injury; the oxygen-derived superoxide and hydroxyl radicals are less toxic to gastric mucosal cells than hydrogen peroxide; and intracellular glutathione, which detoxifies hydrogen peroxide, may be involved in antioxidant defense mechanisms."( Oxygen metabolite-induced cytotoxicity to cultured rat gastric mucosal cells.
Hiraishi, H; Ivey, KJ; Ota, S; Sugimoto, T; Terano, A, 1987
)
0.27
"In order to elucidate toxic and protective mechanisms responsible for allopurinol-induced nephrotoxicity in rats, we investigated changes in plasma creatinine concentration, renal lipid peroxidation, and renal activities of xanthine oxidase, superoxide dismutase and catalase, as enzymatic factors in producing and scavenging oxygen radicals."( Possible mechanism responsible for allopurinol-nephrotoxicity: lipid peroxidation and systems of producing- and scavenging oxygen radicals.
Sudo, J; Suzuki, Y, 1987
)
0.46
" Vitamin E neutralized the toxic effect of free radicals in vitro."( Toxicity of free radicals to mesothelial cells and peritoneal membrane.
Breborowicz, A; Martis, L; Oreopoulos, DG; Serkes, KD; Wieczorowska, K; Witowski, J, 1993
)
0.29
" RINm5F cells were also susceptible to butylalloxan, a lipophilic alloxan derivative that is selectively toxic to pancreatic beta-cells."( Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species.
Lenzen, S; Lortz, S; Munday, R; Tiedge, M, 1998
)
0.3
" The majority of adverse events were mild-to-moderate in intensity."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" However, adenine (250 microm) acts synergistically with a nontoxic dose of DF (150 nm) to produce growth inhibition and adenine nucleotide pool expansion comparable to that observed with a toxic concentration of the herbicide alone (300 nm)."( Adenine nucleotide pool perturbation is a metabolic trigger for AMP deaminase inhibitor-based herbicide toxicity.
Ferl, RJ; Laber, B; Lindell, SD; Paul, AL; Sabina, RL, 2007
)
0.34

Pharmacokinetics

A simple HPLC method was developed and validated for the determination of uric acid (UA), xanthine (X) and hypoxAnthine (HX) concentrations in human serum to support pharmacodynamic (PD) studies of a novel x anthine oxidase inhibitor.

ExcerptReferenceRelevance
"25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls)."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
0.3
"A simple HPLC method was developed and validated for the determination of uric acid (UA), xanthine (X) and hypoxanthine (HX) concentrations in human serum to support pharmacodynamic (PD) studies of a novel xanthine oxidase inhibitor during its clinical development."( Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
Cooper, N; Erdmann, C; Fiene, J; Khosravan, R; Lee, JW, 2006
)
0.85
" During the course of the study, blood and urine samples were collected to assess the pharmacokinetics of febuxostat and its metabolites, and its pharmacodynamic effects on uric acid, xanthine and hypoxanthine concentrations after both single and multiple dose administration."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.74
" There appeared to be a linear pharmacokinetic and dose-response (percentage decrease in serum uric acid) relationship for febuxostat dosages within the 10-120 mg range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years."( The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT, 2008
)
0.55

Bioavailability

ExcerptReferenceRelevance
" Enhanced ROS production (especially superoxide anion) causes diminished NO bioavailability and leads to endothelial dysfunction, which occurs for example in impaired vasorelaxation."( [Oxidative stress in hypertension].
Bełtowski, J; Jamroz, A; Wójcicka, G, 2004
)
0.32
" In terms of the bioavailability of caffeine, the most important factor seemed to be the residence time in the ascending and transverse colon."( Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet constant-release drug delivery system.
Ariniemi, K; Hietanen, H; Kanerva, H; Kekki, T; Lindevall, K; Lipponen, M; Marvola, J; Marvola, M; Mykkänen, S; Slot, L, 2004
)
0.32
" Furthermore, these stores, albeit small, may provide an additional mechanism for the regulation of vascular tone, especially under conditions, such as diabetes, in which nitric oxide generation or bioavailability is compromised; however, additional studies are required to determine not only whether there are additional chemical storage forms of nitric oxide, but also the location of such stores."( Nitrosothiol stores in vascular tissue: modulation by ultraviolet light, acetylcholine and ionomycin.
Cheng, ZJ; Ding, H; Ellis, A; Hollenberg, MD; Jiang, Y; Li, Y; Ng, ES; Triggle, CR, 2007
)
0.34

Dosage Studied

TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration. Allopurinal dosage should be reduced or discontinued if xAnthine nephropathy is suspected.

ExcerptRelevanceReference
" It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol."( Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Birkett, DJ; Day, RO; Hayes, J; Miners, JO; Naidoo, D; Savdie, E; Whitehead, A, 1988
)
0.27
" The animals were killed 5 min after dosing to minimize the conversion of alpha-tocopheryl acetate to alpha-tocopherol."( Comparison of the antioxidant properties of alpha-tocopherol and alpha-tocopheryl acetate in newborn rabbit lung.
Cook, J; Knight, M; Roberts, RJ; Wispe, J, 1987
)
0.27
" Plasma oxipurinol concentrations correlated directly with both allopurinol dosage and with renal glomerular function as reflected by the plasma creatinine concentration."( Plasma oxipurinol concentrations during allopurinol therapy.
Cross, M; Emmerson, BT; Gordon, RB; Thomson, DB, 1987
)
0.27
" On the other hand, when normal lymphocytes were incubated with the xanthine-xanthine oxidase system (X-XO), a known superoxide anion generator, this elicited a dose-response positive angiogenic reaction in normal recipient mice."( Inhibition of lymphocyte-induced angiogenesis by free radical scavengers.
Davel, LE; de Lustig, ES; Monte, M, 1994
)
0.52
" The vessels were resuspended in Krebs buffer and cumulative dose-response curves to norepinephrine reevaluated."( Effects of reactive oxygen metabolites on norepinephrine-induced vasoconstriction.
Benoit, JN; Gao, H; Korthuis, RJ, 1994
)
0.29
" The present study was undertaken to confirm this finding, to determine its dose-response relationship and to identify the underlying mechanism of action."( Dose-dependent uricosuric effect of ambroxol.
Cornelissen, PJ; Jonkman, JH; Oosterhuis, B; Sollie, FA; Storm, G; Su, CA, 1993
)
0.29
" Four of these individuals were additionally dosed with 200 mg allopurinol intravenously."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
0.3
" In addition, TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration, indicating that TEI-6720 and allopurinol have similar pharmacological characteristics although the dosage required differs."( A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M, 1999
)
0.73
" These results show that creatine supplementation in the dosage used in this study had no influence on muscle metabolic response or TBV."( Effect of creatine supplementation on muscle metabolic response to a maximal treadmill exercise test in Standardbred horses.
Essén-Gustavsson, B; Persson, SG; Schuback, K, 2000
)
0.31
" After constricting the vessels with phenylephrine, an acetylcholine dose-response curve was obtained while monitoring changes in diameter by videomicroscopy."( Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox).
Carretero, OA; Garvin, JL; Li, XC; Pagano, PJ; Rey, FE, 2002
)
0.31
" However, PFC emulsions are not resuscitation fluids because PFCs only work optimally in the presence of high O2 partial pressure (hyperoxia); moreover, because they have no oncotic potential, dosing limitations prevent their use to permanently replace large hemorrhage volumes."( Oxygent as a top load to colloid and hyperoxia is more effective in resuscitation from hemorrhagic shock than colloid and hyperoxia alone.
Bottino, D; Faithfull, S; Habler, OP; Keipert, PE; Kemming, GI; Meier, J; Meisner, FG; Minor, T; Packert, KB; Thiel, M; Tillmanns, J; Wojtczyk, CJ, 2005
)
0.33
" Quality control samples were prepared in control serum from individuals not dosed with the xanthine oxidase inhibitor."( Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.
Cooper, N; Erdmann, C; Fiene, J; Khosravan, R; Lee, JW, 2006
)
0.85
"88 mg/dL) for all doses and was dose linear for the 10-120 mg/day dosage range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" There appeared to be a linear pharmacokinetic and dose-response (percentage decrease in serum uric acid) relationship for febuxostat dosages within the 10-120 mg range."( Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT, 2006
)
0.55
" Allopurinal dosage should be reduced or discontinued if xanthine nephropathy is suspected."( Acute renal failure from xanthine nephropathy during management of acute leukemia.
Bakdash, S; Ellis, D; Krishnamurti, L; LaRosa, C; McMullen, L; Moritz, ML; Wu, HY, 2007
)
0.89
" Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years."( The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT, 2008
)
0.55
" The 1 mM dosage of homocysteine in staurosporine-differentiated RGC-5 cells also did not induce cell death above control levels, although 18 hr treatment of non-differentiated RGC-5 cells with 5 mM homocysteine decreased survival by 50%."( Sensitivity of staurosporine-induced differentiated RGC-5 cells to homocysteine.
Allen, JB; Bozard, BR; Dun, Y; Duplantier, J; Farooq, A; Ganapathy, PS; Ha, Y; Smith, SB, 2010
)
0.36
" IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively."( Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma, T; Oishi, R; Okabe, Y; Otsubo, K; Sugitani, A; Tanaka, M; Teshima, D; Yosida, T, 2010
)
0.36
" Next, we carried out a 7-day simultaneous treatment study by two daily treatments, that is, FYX-051 (6 mg/kg) and citrate (2,000 mg/kg), followed by citrate-alone treatment, under the conditions of selected dosing intervals, the second dose of citrate, and dosing volume."( Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Ashizawa, N; Matsumoto, K; Moto, M; Nagata, O; Shimo, T; Taniguchi, T, 2011
)
0.58
" The dosage used and the effect of allopurinol in this population, either or not undergoing therapeutic hypothermia (TH), were evaluated."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
0.93
" The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
xanthineA purine nucleobase found in humans and other organisms.
xanthineA purine nucleobase found in humans and other organisms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (73)

PathwayProteinsCompounds
Metabolism14961108
Nucleotide metabolism89125
Nucleotide catabolism3671
Purine catabolism2051
Purine Metabolism3766
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Purine Ribonucleosides Degradation717
Adenosine Nucleotides Degradation813
AMP Degradation (Hypoxanthine Route)413
Mitochondrial DNA Depletion Syndrome3566
guanosine nucleotides degradation III012
adenosine nucleotides degradation II013
xanthine and xanthosine salvage07
inosine 5'-phosphate degradation013
guanosine nucleotides degradation II125
adenosine nucleotides degradation I327
caffeine degradation I (main, plants)05
theobromine biosynthesis II (via xanthine)06
superpathway of purines degradation in plants745
nucleobase ascorbate transport I16
ureide biosynthesis220
urate conversion to allantoin I311
superpathway of guanosine nucleotides degradation (plants)227
guanosine nucleotides degradation I226
purine nucleotides degradation I (plants)334
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
XMP + Pyrophosphate = Xanthine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
Xanthosine + Orthophosphate = Xanthine + D-Ribose 1-phosphate ( Purine nucleotides and Nucleosides metabolism )13
Purine metabolism1336
Organic Nitrogen Assimilation436
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
guanosine nucleotides degradation416
adenosine nucleotides degradation818
purine ribonucleosides degradation to ribose-1-phosphate316
urate biosynthesis/inosine 5'-phosphate degradation612
purine nucleotides degradation1129
theophylline degradation315
adenosine nucleotides degradation II1427
adenosine nucleotides degradation I227
purine nucleotides degradation I (plants)234
purine ribonucleosides degradation822
purine nucleotides degradation II (aerobic)2246
inosine 5'-phosphate degradation1324
purine nucleobases degradation I (anaerobic)240
purine nucleobases degradation II (anaerobic)051
caffeine degradation IV (bacteria, via demethylation and oxidation)016
caffeine degradation I (main, plants)04
caffeine degradation III (bacteria, via demethylation)521
xanthine and xanthosine salvage312
guanosine nucleotides degradation III1425
superpathway of purines degradation in plants645
salvage pathways of guanine, xanthine and their nucleosides310
superpathway of purine nucleosides salvage920
salvage pathways of purine nucleosides021
salvage pathways of adenine, hypoxanthine, and their nucleosides023
salvage pathways of guanine, xanthine, and their nucleosides017
salvage pathways of purine nucleosides I027
purine nucleotides degradation III (anaerobic)627
purine nucleotides degradation IV (anaerobic)1035
urate biosynthesis410
Folic acid network070
Ureide biosynthesis017
Selenium micronutrient network095
Biochemical pathways: part I0466
Caffeine and theobromine metabolism011
Purine metabolism and related disorders2353
Molybdenum cofactor (Moco) biosynthesis78
ureide biogenesis417
Purine metabolism938
Urate synthesis211

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.05010.010039.53711,122.0200AID588545
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)50.00000.00001.559910.0000AID759421
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)9.00000.00000.933210.0000AID759422
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki130.00000.00061.353610.0000AID187182
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki130.00000.00021.494010.0000AID187182
Guanine deaminaseHomo sapiens (human)Ki1.96001.88003.63405.5500AID502390
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)100.00000.00030.708110.0000AID74022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Xanthine dehydrogenase/oxidaseBos taurus (cattle)Km21.40001.80002.78003.7000AID363291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (82)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
allantoin metabolic processGuanine deaminaseHomo sapiens (human)
nucleobase-containing compound metabolic processGuanine deaminaseHomo sapiens (human)
guanine catabolic processGuanine deaminaseHomo sapiens (human)
deoxyguanosine catabolic processGuanine deaminaseHomo sapiens (human)
nervous system developmentGuanine deaminaseHomo sapiens (human)
amide catabolic processGuanine deaminaseHomo sapiens (human)
GMP catabolic processGuanine deaminaseHomo sapiens (human)
dGMP catabolic processGuanine deaminaseHomo sapiens (human)
guanine metabolic processGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
zinc ion bindingGuanine deaminaseHomo sapiens (human)
guanine deaminase activityGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
cytosolGuanine deaminaseHomo sapiens (human)
cytosolGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID274549Inhibition of human HGPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID502390Inhibition of GDA by colorimetric assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID453743Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 150 m2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID1146438Activity at bovine milk xanthine oxidase assessed as reduction of cytochrome c and phenazine methosulfate1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidines.
AID66419Inhibitory concentration against Enzymatic A chain of ricin (RTA) using Artemia salina ribosomes2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition.
AID239883Acid dissociation constant was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID363291Activity of bovine xanthine oxidase2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
AID75917Positive chronotropic effect on isolated guinea pig right atrium (heart stimulation).1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID453742Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 150 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID32155Affinity against adenosine A1 receptor in the brain membranes by the displacement of [3H]CPX.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID274562Inhibition of human HGPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID227877Ratio of stimulatory activity in right atrium to relaxant activity in tracheal muscle1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID74022Relaxant activity on the spontaneous tone of isolated guinea pig tracheal ring chains.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID252792Insulin release in rat pancreatic beta-cells after 15 minutes of administration at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID1146449Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidines.
AID202405Compound was screened for their ability to potentiate [Ca2+] release induced by cADRP(an endogenous modulator of ryanodine receptor) in sea urchin egg homogenates at a concentration of 2 mM1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Potentiation of cADPR-induced Ca(2+)-release by methylxanthine analogues.
AID705460Antiapicomplexan activity against Toxoplasma gondii THdhxgTRP tachyzoites harboring insertional mutation assessed as growth inhibition after 6 weeks2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Salicylanilide inhibitors of Toxoplasma gondii.
AID759421Inhibition of human BuChE using S-butyrylthiocholine iodide as substrate treated 5 mins before substrate addition measured up to 4 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations.
AID274554Antimalarial activity against Plasmodium falciparum 3D7 at 130 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1146439Activity at bovine milk xanthine oxidase assessed as reduction of 2,6-dichlorophenol-indophenol1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidines.
AID502389Inhibition of GDA-mediated microtubule assembly2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID759422Inhibition of human AChE using acetylthiocholine iodide as substrate treated 5 mins before substrate addition measured up to 4 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations.
AID187182Inhibition of adenosine stimulated accumulation of cyclic AMP at Adenosine A2 receptor of VA13 fibroblasts of rat1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID219846Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID55471Binding affinity to DNA intercalator Acridine orange.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
AID453746Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 10 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID363284Inhibition of Escherichia coli thymidine phosphorylase at 158 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
AID274551Inhibition of [3H]hypoxanthine uptake into Plasmodium falciparum 3D7 at 130 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID453745Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 10 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID274563Inhibition of Plasmodium falciparum HGXPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID252796Insulin release in rat pancreatic beta-cells (PBS-rinsing of the islets) after 15 minutes of administration at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,896)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990387 (20.41)18.7374
1990's592 (31.22)18.2507
2000's488 (25.74)29.6817
2010's320 (16.88)24.3611
2020's109 (5.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.94 (24.57)
Research Supply Index7.61 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index144.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (79.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (1.87%)5.53%
Reviews58 (2.94%)6.00%
Case Studies79 (4.00%)4.05%
Observational1 (0.05%)0.25%
Other1,800 (91.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]